Lanean...
GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...
Gorde:
| Argitaratua izan da: | BMC Med Inform Decis Mak |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469913/ https://ncbi.nlm.nih.gov/pubmed/32580715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12911-020-01149-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|